These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26547065)

  • 41. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetics in cancer: Fundamentals and Beyond.
    Biswas S; Rao CM
    Pharmacol Ther; 2017 May; 173():118-134. PubMed ID: 28188812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges.
    Gerhauser C
    Top Curr Chem; 2013; 329():73-132. PubMed ID: 22955508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer epigenetics.
    Taby R; Issa JP
    CA Cancer J Clin; 2010; 60(6):376-92. PubMed ID: 20959400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genistein, an epigenome modifier during cancer prevention.
    Zhang Y; Chen H
    Epigenetics; 2011 Jul; 6(7):888-91. PubMed ID: 21610327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Epigenetics in Cancer.
    Bennett RL; Licht JD
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():187-207. PubMed ID: 28992434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic and epigenetic regulations of prostate cancer by genistein.
    Molinié B; Georgel P
    Drug News Perspect; 2009 Jun; 22(5):247-54. PubMed ID: 19609462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Curcumin as a regulator of epigenetic events.
    Teiten MH; Dicato M; Diederich M
    Mol Nutr Food Res; 2013 Sep; 57(9):1619-29. PubMed ID: 23754571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural compounds as cancer chemopreventive and chemotherapeutic agents: insights gained from mechanistic and pharmacologic studies.
    Zhu BT
    Anticancer Agents Med Chem; 2012 Dec; 12(10):1157-8. PubMed ID: 22583401
    [No Abstract]   [Full Text] [Related]  

  • 50. Development and classes of epigenetic drugs for cancer.
    Dhanak D; Jackson P
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):58-69. PubMed ID: 25016182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of DNA methylation in cancer development.
    Luczak MW; Jagodziński PP
    Folia Histochem Cytobiol; 2006; 44(3):143-54. PubMed ID: 16977793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural Compounds as Epigenetic Regulators of Human Dendritic Cell-mediated Immune Function.
    Mirza S; Shah K; Patel S; Jain N; Rawal R
    J Immunother; 2018 May; 41(4):169-180. PubMed ID: 29239917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
    Katz TA; Huang Y; Davidson NE; Jankowitz RC
    Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
    Jankowska AM; Millward CL; Caldwell CW
    Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic targeting therapies to overcome chemotherapy resistance.
    Balch C; Nephew KP
    Adv Exp Med Biol; 2013; 754():285-311. PubMed ID: 22956507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The epigenome as a target for cancer chemoprevention.
    Kopelovich L; Crowell JA; Fay JR
    J Natl Cancer Inst; 2003 Dec; 95(23):1747-57. PubMed ID: 14652236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
    Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
    Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.